Showing results (21-30 of 140) with videos related to
Sort By:
Pageof 14
Prostaglandins, Leukotrienes, and Medicine|June 1, 1983
Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patientsP H Vlasses, R K Ferguson, J B Smith, et al.The Journal of Laboratory and Clinical Medicine|July 1, 1983
Dimethyl sulfoxide inhibits bioactivation of sulindacB N Swanson, V K Boppana, P H Vlasses, et al.Journal of Clinical Pharmacology|July 1, 1982
A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertensionR K Ferguson, P H Vlasses, J D Irvin, et al.Antimicrobial Agents and Chemotherapy|February 1, 1983
Norfloxacin disposition after sequentially increasing oral dosesB N Swanson, V K Boppana, P H Vlasses, et al.Clinical Pharmacology and Therapeutics|May 1, 1985
Effects of cimetidine and ranitidine on the conversion of prednisone to prednisoloneM A Sirgo, M L Rocci, R K Ferguson, et al.Research Communications in Chemical Pathology and Pharmacology|September 1, 1981
Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitroB N Swanson, M Hichens, P Mojaverian, et al.Journal of Clinical Pharmacology|November 1, 1988
Antihypertensive response to ketanserin: influence of race and weightT Kosoglou, M D Cressman, P H Vlasses, et al.Journal of Clinical Pharmacology|April 1, 1987
Hemodynamic effects during rest and exercise of bucindolol in hypertensive menD P Conner, P H Vlasses, R A Clementi, et al.Journal of Pharmaceutical Sciences|April 1, 1986
Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitorP Mojaverian, M L Rocci, P H Vlasses, et al.Clinical Pharmacology and Therapeutics|September 1, 1982
Sulindac disposition when given once and twice dailyB N Swanson, V K Boppana, P H Vlasses, et al.Pageof 14